title: [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
abstract: OBJECTIVE
  To evaluate the safety and efficiency of using abiraterone and prednisone in the treatment of patient with metastatic castration resistant prostate cancer (mCRPC) no prior chemotherapy.
  
  
  METHODS
  Three mCRPC no prior chemotherapy patients accepted abiraterone and prednisone treatment. The clinical data were analyzed retrospectively and the safety and efficiency of this treatment option were discussed. The Gleason scores of the three mCRPC patients were 5, 9, and 9. The clinical stages were T3aNxM0, T3aNxM1b, and T3aNxM1b. The patients received abiraterone 1 000 mg daily and prednisone 5 mg twice daily and androgen deprivation therapy in the treatment. Their blood pressure, complete blood count, prostate specific antigen (PSA), biochemical parameters, whole body CT scan and bone scan were done regularly to monitor the progression of the diseases.
  
  
  RESULTS
  In this study, the general condition improved in two patients. Two of the three patients experienced decrease of PSA and no progression. One patient experienced disease progression. Generally, abiraterone and prednisone resulted in prolonged radiographic progression-free survival and delayed in PSA progression in mCRPC no prior chemotherapy. There were no severe side effects, such as hypokalemia, hypertension, and water-sodium retention. The patient's tolerance was good.
  
  
  CONCLUSIONS
  Abiraterone and prednisone are safe and can improve mCRPC no prior chemotherapy patient's life quality and may prolong the overall survival.
authors.affiliation: Department of Urology, Beijing Hospital of the Ministry of Health, Beijing 100730, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Ma
authors.affiliation: Department of Urology, Beijing Hospital of the Ministry of Health, Beijing 100730, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Zhu
authors.affiliation: Department of Urology, Beijing Hospital of the Ministry of Health, Beijing 100730, China.
authors.forename: Ben
authors.initials: B
authors.lastname: Wan
authors.affiliation: Department of Urology, Beijing Hospital of the Ministry of Health, Beijing 100730, China.
authors.forename: Peng-jie
authors.initials: PJ
authors.lastname: Wu
authors.affiliation: Department of Urology, Beijing Hospital of the Ministry of Health, Beijing 100730, China.
authors.forename: Jian-ye
authors.initials: JY
authors.lastname: Wang
mesh_terms: D000069501:Abiraterone Acetate; D000736:Androstenes / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011241:Prednisone / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D012189:Retrospective Studies
chemical_list: D000736:Androstenes; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate; D011241:Prednisone